Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > LATEST
LATEST
-
BUSINESS Amgen Ends Rocatinlimab Pact with Kyowa Kirin
February 3, 2026
-
BUSINESS AstraZeneca Names Andy Barnett as New Japan President
February 3, 2026
-
BUSINESS Shionogi Eyes Faster QOL Biz Expansion with Ex-JT Researchers: CEO
February 2, 2026
-
BUSINESS Sumitomo Flags Diabetes Pipeline Gap as Key Strategic Issue: CEO
February 2, 2026
-
BUSINESS Astellas, MSD Seek Japan Nod for Padcev/Keytruda in Perioperative MIBC
February 2, 2026
-
BUSINESS Alfresa Launches End-to-End Platform to Support Biotech Entry into Japan
February 2, 2026
-
BUSINESS Nichi-Iko’s Xarelto Generic Adds VTE Use
February 2, 2026
-
REGULATORY Public Comments Warn Japan’s Drug Pricing System Cannot Reflect Inflation: Chuikyo
February 2, 2026
-
BUSINESS Ohara Files Japan NDA for Jazz’s Diffuse Midline Glioma Drug
February 2, 2026
-
BUSINESS Takeda Files ImmunoGen-Paired ADC for Ovarian Cancer in Japan
February 2, 2026
-
REGULATORY Chuikyo Agrees to Apply Originator Optimal-Use Guidelines to Biosimilars
February 2, 2026
-
BUSINESS Fuji Says Eylea Biosimilar Patent Risk Cleared under Global Settlement
February 2, 2026
-
REGULATORY MHLW Panel Sets Safety Rules for Upcoming Pomalyst Generics
February 2, 2026
-
BUSINESS Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit
January 30, 2026
-
BUSINESS FDA Places Clinical Hold on MPS Gene Therapies: Regenxbio/Nippon Shinyaku
January 30, 2026
-
BUSINESS Astellas Positions Izervay as Key Entry Drug in Ophthalmology Push
January 30, 2026
-
BUSINESS Chugai Logs Solid 2025 Results on Overseas Growth, Profit Margin Nears 50%
January 30, 2026
-
BUSINESS Zynlonta Hits Primary Endpoint in Japanese PI/II Study: Tanabe
January 30, 2026
-
BUSINESS Towa Chief Urges Better Use of Innovators’ LLP Manufacturing Assets, Calls Otsuka Deal a “First Step”
January 30, 2026
-
REGULATORY Japan Panel Green-Lights Pfizer’s Tukysa, Wider Labels for Tezspire, and More Drugs
January 30, 2026
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…